Press Release
RepliCel CEO Provides Updated Outlook
Partnership and Investment Fuel Plans for Upcoming Advancements VANCOUVER, Oct. 15, 2018 /CNW/ - RepliCel...
Press Release
RepliCel Life Sciences Completes Financing with YOFOTO (China) Health
 YOFOTO (China) Health and RepliCel Life Sciences finalize investment and commence collaboration activity in Greater...
Press Release
RepliCel Life Sciences and YOFOTO (China) Health Obtain All Approvals Needed to Complete Investment
YOFOTO (China) Health and RepliCel Life Sciences now cleared to close investment transaction and commence...
As Seen In
Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) and YOFOTO Health Industry Co. Ltd. received approval from...
As Seen In
Canadian Technology and Innovation: making strides in the global cell therapy landscape
Another cell therapy rising star, RepliCel Life Sciences, is harnessing the healing properties of hair...
As Seen In
9 Challenges Keeping Cell And Gene Therapy Executives Up At Night
Despite recent progress in regenerative medicine, cell and gene therapy executives are still pioneering many...
Press Release
RepliCel Life Sciences Announces Signed Licensing and Co-Development Deal for Greater China
Skin rejuvenation and tendon regeneration products to be commercialized in Greater China in partnership with...
As Seen In
Is the Age-Old Quest for a Baldness Cure Reaching Its End?
Click here to read the full article and interview as it appears in The New...
As Seen In
RepliCel's regenerative technology could take the "Polar Silk Road" to China
New opportunities are arising at every turn for the regenerative medicine community. READ ARTICLE ...
Press Release
RepliCel Life Sciences Now Finalizing its Strategic Investment Partnership with China-based YOFOTO
A revised binding term sheet reflects improved terms and positions the parties for closing the...
As Seen In
Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance...
Press Release
RepliCel CEO Provides 2018 Shareholder Update
With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for...
As Seen In
From stem cells to revenue: Bringing regenerative medicine to the masses
RepliCel lands Asian partnership to optimize the development of its biotech solutions for chronic conditions....
Press Release
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater...
2018 EBD Biotech Showcase
RepliCel presented and conducted one-on-one partnering meetings.
As Seen In
RepliCel CEO: Anticipating the Approval of Their Dermal Injector, its Impact in Europe and Beyond
Click here to read the full article and interview as it appears in Life Science:...
As Seen In
Japan is Fertile Ground for Biotech Deal
Click here to read the full article as it appears in the Streetwise Reports: The...
Press Release
RepliCel Life Sciences Successfully Closes Financing
Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy VANCOUVER,...
As Seen In
Company Uses Patients' Own Cells to Put an End to Baldness, Aging Skin and Tendon Degeneration
Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon...
As Seen In
Regenerative medicine: Interview with a game-changing leader
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal...

The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.